COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
11/03/2026
Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
11/03/2026
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and [...]
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026
Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue [...]
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a [...]
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026
Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “ [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
Encouraging Sports Enthusiasts to Move Better Through Smarter Recovery New York, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign "Train Hard, [...]
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
11/03/2026
2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year ; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 [...]
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior [...]
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
11/03/2026
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or [...]
Lighter. Cheaper. Funner. Pub Light Is Here.
11/03/2026
Pub Beer introduces a 99‑calorie American‑style light lager at 4% ABV BEND, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Pub Beer , the Cheap Fun beer brand by Tilray Brands, Inc . (Nasdaq: TLRY; TSX: TLRY), today announced [...]
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 16, 2026, as set out below. The report by the Board of Directors was [...]
AiM Medical Robotics adds surgical robotics pioneer, Dr. Yulun Wang, to its world-class Board
11/03/2026
— Renowned founder and robotics visionary joins AiM at a pivotal growth inflection point — WORCESTER, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics Inc. (AiM), a company developing next-generation MRI- [...]
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease First person has been dosed [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign, " Train Hard, Recover Smart ," encouraging sports enthusiasts worldwide to take a [...]
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
11/03/2026
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis treatment [...]
Beyond Air to Participate in the 38th Annual Roth Conference in March
11/03/2026
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
11/03/2026
Company Reports Record Revenue and Profitability for Full-Year 2025 REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company [...]
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
11/03/2026
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas [...]

Pages